Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”

Forest plots illustrate the mean difference in; (A) hospital stay, (B) ICU stay, (C) intubation time; with subgroup analysis. by Mohamed R. Abdelraouf (21501468)

Statins induced flatter neuronal somas. by Shuk C. Tsoi (21192243)

Mean (95% CI) and standard deviation of Co-Contraction index of right and left gluteus medius (MVC%) during 60 minutes standing between two groups. by Saeedeh Abbasi (9423189)

Statins resulted in smaller neuronal soma size. by Shuk C. Tsoi (21192243)

“…Within control birds, the BrdU + /Hu+ neuron population was significantly smaller in soma size than the BrdU-/Hu+ older, heterogeneous population (A). …”

Maximum likelihood estimates of trans-log mean stochastic function. by James Anaba Akolgo (14129379)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

The small blue circles show the IC-volume (mean of left and right) from 72 males and the small red squares from 51 females as a function of age. by Pingling Kwok (14896191)